Omeros Corporation - Common Stock (OMER)

14.01
-0.54 (-3.71%)
NASDAQ · Last Trade: Nov 19th, 5:58 PM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Omeros (OMER) Q3 2026 Earnings Call Transcriptfool.com
YARTEMLEA gained hospital access as gross product revenue rose 30% this quarter.
Via The Motley Fool · November 17, 2026
Omeros Q3 Earnings Call Highlightsmarketbeat.com
Omeros (NASDAQ:OMER) reported higher third-quarter sales of its transplant complication treatment YARTEMLEA and a second consecutive quarter of positive operating cash flow, while a non-cash adjustment tied to its convertible notes pushed the company to a net loss. YARTEMLEA generated $35.9 million
Via MarketBeat · November 16, 2026
Omeros (NASDAQ:OMER) Q3 Revenue Miss Overshadows EPS Beat as YARTEMLEA Launch Faces Scrutinychartmill.com
Via Chartmill · November 16, 2026
After-Hours Market Movers: Microcaps and Small Caps Post Sharp Gains and Losseschartmill.com
Via Chartmill · November 16, 2026
Omeros Corp (NASDAQ:OMER) Swings to Profit on YARTEMLEA Launch, Topping EPS Forecastschartmill.com
Via Chartmill · May 13, 2026
Omeros Corp (NASDAQ:OMER) Reports Q4 2025 Earnings Boosted by Major Asset Sale, Launches First Commercial Productchartmill.com
Via Chartmill · March 31, 2026
Omeros (OMER) Q2 2026 Earnings Call Transcriptfool.com
Yartemlia generated $32.2M in gross sales during its first full quarter on market.
Via The Motley Fool · August 19, 2026
Let's take a look at the stocks that are in motion in today's session.chartmill.com
Via Chartmill · August 13, 2026
There are notable gap-ups and gap-downs in today's session.chartmill.com
Via Chartmill · August 13, 2026
These stocks are moving in today's pre-market sessionchartmill.com
Via Chartmill · August 13, 2026
Omeros Q2 Earnings Call Highlightsmarketbeat.com
Omeros (NASDAQ:OMER) reported second-quarter net sales of $28.5 million for YARTEMLEA, its newly launched treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA, as the company generated positive operating cash flow and reduced its convertible debt after th
Via MarketBeat · August 12, 2026
12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga.com
Gainers ENvue Medical (NASDAQ:FEED) shares rose 49.1% to $0.61 during Wednesday's after-market session. The market value of their outstanding shares is at $2.4 million. Omeros (NASDAQ:OMER) stock moved upwards by
Via Benzinga · August 12, 2026
What's going on in today's after hours sessionchartmill.com
Via Chartmill · August 12, 2026
Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026?fool.com
Heartflow boasts rapid AI-driven growth but faces reimbursement headwinds, while Omeros bets everything on its first commercial launch.
Via The Motley Fool · July 8, 2026
Which stocks are moving on Friday?chartmill.com
Via Chartmill · June 26, 2026
Traders are paying attention to the gapping stocks in Friday's session.chartmill.com
Via Chartmill · June 26, 2026
Top movers in Friday's pre-market sessionchartmill.com
Via Chartmill · June 26, 2026
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?fool.com
Both companies target serious health challenges, but their financials and risk profiles reveal sharply different paths for growth-focused investors.
Via The Motley Fool · June 22, 2026
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?fool.com
Intellia's CRISPR pipeline and Omeros's newly approved therapy each bring unique risk and reward profiles, see how their financials and partnerships compare.
Via The Motley Fool · June 20, 2026
Omeros (OMER) Q4 2025 Earnings Transcriptfool.com
Omeros (OMER) Q4 2025 Earnings Transcript
Via The Motley Fool · June 1, 2026
Omeros (OMER) Q1 2026 Earnings Transcriptfool.com
Omeros (OMER) Q1 2026 Earnings Transcript
Via The Motley Fool · May 14, 2026
Omeros Q1 Earnings Call Highlightsmarketbeat.com
Omeros (NASDAQ:OMER) reported first-quarter 2026 net income of $56.1 million, or $0.78 per share, as the company began commercial sales of YARTEMLEA, its recently approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA. Chairman and Chief Executive
Via MarketBeat · May 14, 2026
These stocks are gapping in today's sessionchartmill.com
Via Chartmill · April 1, 2026
Nasdaq, S&P 500 Futures Dip As Investors Brace For Jobs Data, Tariff Ruling: Why NVDA, MSFT, AAPL, APLD, NIO Are On Traders' Radar Todaystocktwits.com
Nvidia, Apple, Microsoft, and select biotech names dominated early market buzz.
Via Stocktwits · January 8, 2026
Why Did Omeros Stock Jump 5% In After-Hours Trading Today?stocktwits.com
Yartemlea shipments to wholesalers are expected in the third week of January.
Via Stocktwits · January 7, 2026